Dravet Syndrome Treatment Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast 2023-2027

Published: Dec 2022 Pages: 163 SKU: IRTNTR45344

Dravet Syndrome Treatment Market Forecast 2023-2027

The dravet syndrome treatment market is estimated to grow by USD 575.14 million at a CAGR of 9.6% between 2022 and 2027. The growth of the market depends on several factors, including growth in special regulatory designations, increasing new product launches, and advancements in genetic therapeutics for DS treatment.

What will be the size of the Market During the Forecast Period?

To learn more about this report, Download Report Sample

Market Dynamics

The growth in special regulatory designations is notably driving the market growth, although factors such as low awareness may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Driver

The growth in special regulatory designations is notably driving the market growth. The US Food and Drug Administration (FDA) has developed distinct and successful approaches to the rapid approval of drugs for serious diseases. Regulatory agencies such as the US FDA and EMA grant orphan drug designations, fast-track drug designations, and breakthrough drug designations to speed up the drug development and approval process.

In addition, the US FDA granted orphan drug designation in November 2021 to Neuroene Therapeutics' NT102, which can treat seizure symptoms in Dravet syndrome. In addition, in August 2021, EPIDYOLEX, manufactured by GW Pharmaceuticals, received orphan drug designation from the EMA for the treatment of LGS and DS attacks. These regulatory policies encourage pharmaceutical companies to develop drugs for rare diseases such as DS, which in turn boosts the growth of the global DS treatment market during the forecast period.

Significant Trend

Increased use of new-generation drugs is one of the major market trends. FGDs such as clobazam and valproate have been used in the treatment of DS for decades. However, they are associated with side effects and have a limited therapeutic effect and complex pharmacokinetics.

In the 1990s and early 2000s, SGDs such as stiripentol and topiramate and other antiepileptic drugs such as lamotrigine, levetiracetam, and gabapentin entered the market. Later, as research and development increased, TGDs such as clonazepam, zonisamide, and ethosuximide came on the market. Compared to FGD, new-generation drugs have fewer side effects and wide therapeutic areas. Therefore, the use of new-generation drugs is higher than that of previous generations. However, SGD drugs are used more than TGD because they are more effective in treating DS. Therefore, the introduction of new-generation drugs will contribute to the growth of global DS treatment during the forecast period.

Major Challenge

Low awareness is the major challenge impeding market growth. DS is a rare and severe type of epilepsy in babies. Children usually have psychomotor development before the onset of seizures. In most cases, the first attacks are accompanied by fever, which causes convulsions. In most cases, parents do not understand the symptoms of the disease, and even doctors are not able to recognize the disease as DS. In DS, relapse occurs after the first attacks. Parents are not aware of seizures, and this leads to misunderstandings about the symptoms of the disease. If parents are aware and adequately informed through medical professionals or awareness programs, the second episode of seizures is less painful for children.

Parents should be aware of the high risk of seizures, the treatment options, and the disease. Doctors are less aware of alternative treatments for the disease and usually treat the patient with anti-epileptic drugs. But they are not enough for treatment out of 100. Thus, a lack of awareness among parents and doctors poses a challenge to the growth of the global DS treatment market during the forecast period.

Key Customer Landscape

The market growth analysis report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market growth and forecasting report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Customer Landscape

Who are the Major Dravet Syndrome Treatment Market Companies?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

UCB SA - The company offers Dravet syndrome treatment in the form of an oral solution called FINTEPLA for patients 2 years of age and older. 

The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about 15 market Companies, including:

  • AbbVie Inc.
  • BIOCODEX SAS
  • Cadila Healthcare Ltd.
  • Encoded Therapeutics Inc.
  • Epygenix Therapeutics Inc.
  • H Lundbeck AS
  • Jazz Pharmaceuticals Plc
  • Johnson and Johnson
  • Lupin Ltd.
  • PTC Therapeutics Inc.
  • Stoke Therapeutics Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Supernus Pharmaceuticals Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Thermo Fisher Scientific Inc.

Qualitative and quantitative analysis of Companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize Companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize Companies as dominant, leading, strong, tentative, and weak.

Market Segmentation

The market share growth of the SGDs segment will be significant during the forecast period. SGDs are the largest segment of the global DS treatment market in 2022 and will continue to remain the largest segment during the forecast period. SGDs are widely used for the treatment of DS, as they are advantageous over FGDs regarding pharmacokinetics, safety, and tolerability. Currently, stiripentol and topiramate are the only available SGDs for the treatment of DS. 

Get a glance at the market contribution of various segments Request a PDF Sample

The second-generation drug (SGDs) segment was valued at USD 274.97 million in 2017 and continued to grow until 2021. Another anti-epileptic agent that acts through multiple mechanisms is Topiramate. It helps in the blockage of voltage-gated-dependent sodium channels, carbonic anhydrase enzyme inhibition, aminomethylphosphonic acid (AMPA)/kainite receptor antagonism, and by enhancing the activity of gamma-aminobutyric acid (GABA) at GABA receptors. Thus, the increasing prevalence of DS, especially among children, will increase the demand for stiripentol and topiramate, which will boost the development of the SGDs segment of the global DS treatment market during the forecast period.

Regional Analysis

For more insights on the market share of various regions Request PDF Sample now!

North America is estimated to contribute 38% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

North America is the largest geographical segment of the global DS treatment market in 2022 and will continue to remain the largest segment during the forecast period. This is primarily due to increasing initiatives and funding by various organizations to support the development of new treatments for DS.

The US and Canada are the major revenue contributors to the DS treatment market in North America. The market in these countries is driven by the presence of established medical facilities and the increasing healthcare spending by individuals.

Market Analyst Overview

The Dravet Syndrome Treatment Market, primarily in the United States, has witnessed significant advancements since June 2018, with regulatory approvals for medications like Stiripentol (Diacomit) and Epidiolex, a cannabidiol-based drug derived from marijuana. These breakthroughs, along with the emergence of Zogenix's ZX008 (Fintepla), have revolutionized treatment options for Dravet Syndrome patients. Medical equipment, research centers, and physicians play vital roles in diagnosing and managing the condition, characterized by myoclonic, partial, and absence seizures. Hospitals, diagnostic laboratories, and academic institutes collaborate to provide comprehensive care to epilepsy patients, utilizing antiepileptic medications and innovative therapies. The Dravet Foundation supports research initiatives and fosters collaboration among end-users, including healthcare professionals and patients, to improve outcomes and quality of life for individuals affected by this rare neurological disorder.

Segment Overview

The market forecasting report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

  • Product Outlook (USD Million, 2017 - 2027)
    • SGDs
    • TGDs
    • FDGs
  • Distribution Channel Outlook (USD Million, 2017 - 2027)
    • Hospital pharmacy
    • Retail pharmacy
    • E-Commerce
    • Others
  • Region Outlook (USD Million, 2017 - 2027)
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Aisa
      • China
      • India
      • Singapore
    • Rest of World (ROW)
      • Brazil
      • Argentina
      • Rest of the Middle East & Africa

Dravet Syndrome Treatment Market Scope

Market Report Coverage

Details

Page number

163

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 9.6%

Market growth 2023-2027

USD 575.14 million

Market structure

Fragmented

YoY growth 2022-2023(%)

9.0

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 38%

Key countries

US, Germany, UK, China, and Japan

Competitive landscape

 Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

Key companies profiled

AbbVie Inc., BIOCODEX SAS, Cadila Healthcare Ltd., Encoded Therapeutics Inc., Epygenix Therapeutics Inc., H Lundbeck AS, Jazz Pharmaceuticals Plc, Johnson and Johnson, Lupin Ltd., PTC Therapeutics Inc., Stoke Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Supernus Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., Thermo Fisher Scientific Inc., UCB SA, Viatris Inc., and Xenon Pharmaceuticals Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the market between 2023 and 2027
  • Precise estimation of the market size and its contribution to the parent market
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the industry across North America, Europe, Asia, and Rest of World (ROW)
  • Thorough analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global dravet syndrome treatment market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on Global dravet syndrome treatment market 2017 - 2021 ($ million)
    • 4.2 Product Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Product Segment 2017 - 2021 ($ million)
    • 4.3 Distribution channel Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Distribution channel Segment 2017 - 2021 ($ million)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Product

    • 6.1 Market segments
      • Exhibit 30: Chart on Product - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Product - Market share 2022-2027 (%)
    • 6.2 Comparison by Product
      • Exhibit 32: Chart on Comparison by Product
      • Exhibit 33: Data Table on Comparison by Product
    • 6.3 SGDs - Market size and forecast 2022-2027
      • Exhibit 34: Chart on SGDs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Data Table on SGDs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 36: Chart on SGDs - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on SGDs - Year-over-year growth 2022-2027 (%)
    • 6.4 TGDs - Market size and forecast 2022-2027
      • Exhibit 38: Chart on TGDs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Data Table on TGDs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 40: Chart on TGDs - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on TGDs - Year-over-year growth 2022-2027 (%)
    • 6.5 FDGs - Market size and forecast 2022-2027
      • Exhibit 42: Chart on FDGs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 43: Data Table on FDGs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 44: Chart on FDGs - Year-over-year growth 2022-2027 (%)
      • Exhibit 45: Data Table on FDGs - Year-over-year growth 2022-2027 (%)
    • 6.6 Market opportunity by Product
      • Exhibit 46: Market opportunity by Product ($ million)

    7 Market Segmentation by Distribution Channel

    • 7.1 Market segments
      • Exhibit 47: Chart on Distribution Channel - Market share 2022-2027 (%)
      • Exhibit 48: Data Table on Distribution Channel - Market share 2022-2027 (%)
    • 7.2 Comparison by Distribution Channel
      • Exhibit 49: Chart on Comparison by Distribution Channel
      • Exhibit 50: Data Table on Comparison by Distribution Channel
    • 7.3 Hospital pharmacy - Market size and forecast 2022-2027
      • Exhibit 51: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 52: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 53: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
      • Exhibit 54: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
    • 7.4 Retail pharmacy - Market size and forecast 2022-2027
      • Exhibit 55: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 56: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 57: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%)
      • Exhibit 58: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%)
    • 7.5 E- Commerce - Market size and forecast 2022-2027
      • Exhibit 59: Chart on E- Commerce - Market size and forecast 2022-2027 ($ million)
      • Exhibit 60: Data Table on E- Commerce - Market size and forecast 2022-2027 ($ million)
      • Exhibit 61: Chart on E- Commerce - Year-over-year growth 2022-2027 (%)
      • Exhibit 62: Data Table on E- Commerce - Year-over-year growth 2022-2027 (%)
    • 7.6 Others - Market size and forecast 2022-2027
      • Exhibit 63: Chart on Others - Market size and forecast 2022-2027 ($ million)
      • Exhibit 64: Data Table on Others - Market size and forecast 2022-2027 ($ million)
      • Exhibit 65: Chart on Others - Year-over-year growth 2022-2027 (%)
      • Exhibit 66: Data Table on Others - Year-over-year growth 2022-2027 (%)
    • 7.7 Market opportunity by Distribution Channel
      • Exhibit 67: Market opportunity by Distribution Channel ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 68: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 69: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 70: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 71: Chart on Geographic comparison
      • Exhibit 72: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 73: Chart on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 74: Data Table on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 75: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 76: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 77: Chart on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 78: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 79: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 80: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 81: Chart on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 82: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 83: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 84: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 85: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 86: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 87: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 88: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 89: Chart on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 90: Data Table on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 91: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 92: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 UK - Market size and forecast 2022-2027
      • Exhibit 93: Chart on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 94: Data Table on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 95: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 96: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.9 Germany - Market size and forecast 2022-2027
      • Exhibit 97: Chart on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 98: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 99: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 100: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.10 China - Market size and forecast 2022-2027
      • Exhibit 101: Chart on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 102: Data Table on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 103: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 104: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.11 Japan - Market size and forecast 2022-2027
      • Exhibit 105: Chart on Japan - Market size and forecast 2022-2027 ($ million)
      • Exhibit 106: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
      • Exhibit 107: Chart on Japan - Year-over-year growth 2022-2027 (%)
      • Exhibit 108: Data Table on Japan - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 109: Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 110: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 111: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 112: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 113: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 114: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 115: Matrix on vendor position and classification
            • 12.3 AbbVie Inc.
              • Exhibit 116: AbbVie Inc. - Overview
              • Exhibit 117: AbbVie Inc. - Product / Service
              • Exhibit 118: AbbVie Inc. - Key news
              • Exhibit 119: AbbVie Inc. - Key offerings
            • 12.4 BIOCODEX SAS
              • Exhibit 120: BIOCODEX SAS - Overview
              • Exhibit 121: BIOCODEX SAS - Product / Service
              • Exhibit 122: BIOCODEX SAS - Key offerings
            • 12.5 Encoded Therapeutics Inc.
              • Exhibit 123: Encoded Therapeutics Inc. - Overview
              • Exhibit 124: Encoded Therapeutics Inc. - Product / Service
              • Exhibit 125: Encoded Therapeutics Inc. - Key offerings
            • 12.6 Epygenix Therapeutics Inc.
              • Exhibit 126: Epygenix Therapeutics Inc. - Overview
              • Exhibit 127: Epygenix Therapeutics Inc. - Product / Service
              • Exhibit 128: Epygenix Therapeutics Inc. - Key offerings
            • 12.7 H Lundbeck AS
              • Exhibit 129: H Lundbeck AS - Overview
              • Exhibit 130: H Lundbeck AS - Product / Service
              • Exhibit 131: H Lundbeck AS - Key offerings
            • 12.8 Jazz Pharmaceuticals Plc
              • Exhibit 132: Jazz Pharmaceuticals Plc - Overview
              • Exhibit 133: Jazz Pharmaceuticals Plc - Product / Service
              • Exhibit 134: Jazz Pharmaceuticals Plc - Key news
              • Exhibit 135: Jazz Pharmaceuticals Plc - Key offerings
            • 12.9 Johnson and Johnson
              • Exhibit 136: Johnson and Johnson - Overview
              • Exhibit 137: Johnson and Johnson - Business segments
              • Exhibit 138: Johnson and Johnson - Key news
              • Exhibit 139: Johnson and Johnson - Key offerings
              • Exhibit 140: Johnson and Johnson - Segment focus
            • 12.10 Lupin Ltd.
              • Exhibit 141: Lupin Ltd. - Overview
              • Exhibit 142: Lupin Ltd. - Product / Service
              • Exhibit 143: Lupin Ltd. - Key news
              • Exhibit 144: Lupin Ltd. - Key offerings
            • 12.11 PTC Therapeutics Inc.
              • Exhibit 145: PTC Therapeutics Inc. - Overview
              • Exhibit 146: PTC Therapeutics Inc. - Business segments
              • Exhibit 147: PTC Therapeutics Inc. - Key offerings
              • Exhibit 148: PTC Therapeutics Inc. - Segment focus
            • 12.12 Stoke Therapeutics Inc.
              • Exhibit 149: Stoke Therapeutics Inc. - Overview
              • Exhibit 150: Stoke Therapeutics Inc. - Product / Service
              • Exhibit 151: Stoke Therapeutics Inc. - Key offerings
            • 12.13 Sun Pharmaceutical Industries Ltd.
              • Exhibit 152: Sun Pharmaceutical Industries Ltd. - Overview
              • Exhibit 153: Sun Pharmaceutical Industries Ltd. - Product / Service
              • Exhibit 154: Sun Pharmaceutical Industries Ltd. - Key offerings
            • 12.14 Supernus Pharmaceuticals Inc.
              • Exhibit 155: Supernus Pharmaceuticals Inc. - Overview
              • Exhibit 156: Supernus Pharmaceuticals Inc. - Product / Service
              • Exhibit 157: Supernus Pharmaceuticals Inc. - Key offerings
            • 12.15 Takeda Pharmaceutical Co. Ltd.
              • Exhibit 158: Takeda Pharmaceutical Co. Ltd. - Overview
              • Exhibit 159: Takeda Pharmaceutical Co. Ltd. - Product / Service
              • Exhibit 160: Takeda Pharmaceutical Co. Ltd. - Key news
              • Exhibit 161: Takeda Pharmaceutical Co. Ltd. - Key offerings
            • 12.16 UCB SA
              • Exhibit 162: UCB SA - Overview
              • Exhibit 163: UCB SA - Product / Service
              • Exhibit 164: UCB SA - Key offerings
            • 12.17 Viatris Inc.
              • Exhibit 165: Viatris Inc. - Overview
              • Exhibit 166: Viatris Inc. - Business segments
              • Exhibit 167: Viatris Inc. - Key offerings
              • Exhibit 168: Viatris Inc. - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 169: Inclusions checklist
                • Exhibit 170: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 171: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 172: Research methodology
                • Exhibit 173: Validation techniques employed for market sizing
                • Exhibit 174: Information sources
              • 13.5 List of abbreviations
                • Exhibit 175: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              dravet syndrome treatment market market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis